Blog

May 01, 2023

PEGylated Proteins Market 2023

According to IMARC Group’s latest research report, titled “ PEGylated Proteins

According to IMARC Group's latest research report, titled "PEGylated Proteins Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028," offers a comprehensive analysis of the industry, which comprises insights on the PEGylated proteins market. The report also includes competitor and regional analysis, and contemporary advancements in the market. The global PEGylated proteins market size reached US$ 1.16 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 2.13 Billion by 2028, exhibiting a growth rate (CAGR) of 10.16% during 2023-2028.

Get Free Sample Copy of Report at – https://www.imarcgroup.com/pegylated-proteins-market/requestsample

PEGylated Proteins Market Outlook:

PEGylated proteins are protein molecules that are conjugated with polyethylene glycol (PEG). Its process involves modifying the surface of proteins in order to extend their half-lives and improve their solubility, stability, and bioavailability. The process covalently attaches one or more PEG molecules to the surface of a protein, resulting in a larger, more hydrophilic molecule. The PEG molecules act as a protective shield, shielding the protein from enzymatic degradation, reducing immunogenicity, and enhancing the pharmacokinetic properties of the protein. Additionally, PEGylated proteins are widely used in biopharmaceuticals due to their improved pharmacokinetic properties and extended half-lives, allowing for longer action duration and improved therapeutic efficacy. They are adopted in gene therapy and vaccine delivery as they provide a promising platform for the development of new therapeutic agents to treat a wide range of diseases.

Ask to an Analyst – https://www.imarcgroup.com/request?type=report&id=7070&flag=C

PEGylated Proteins Market Trends:

The escalating healthcare expenditure majorly drives the global market. This can be supported by the growing number of chronic illnesses, such as kidney disorders, autoimmune diseases, genetic disorders, hepatitis, and rheumatoid arthritis, among individuals. Along with this, PEGylated proteins are extensively employed to treat inflammation, deliver corrective genes to cells, prevent blood clots, deliver growth hormones, and check the progression of chronic kidney disease is a major driving factor. Additionally, the rising use of PEGylated proteins in cancer treatment to deliver chemotherapy drugs directly to cancer cells and decrease the side effects on healthy cells is impacting the market favorably. Apart from this, continuous advancements in PEGylation technology, such as the development of new PEGylation techniques that can generate smaller and more complex molecules, are creating a positive market outlook. Some of the other factors driving the market include the rising aging population and the implementation of various government initiatives to boost regulatory standards in the pharmaceutical industry.

Key Market Segmentation:

Competitive Landscape with Key Players:

Product Insights:

Protein Type Insights:

Application Insights:

End User Insights:

Breakup by Region:

Key Highlights of the Report:

Note: If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.

Browse More Reports:

Who we are:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC's information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company's expertise.

Contact us:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: [email protected]